SAREPTA THERAPEUTICS, INC. Interest Expense
SAREPTA THERAPEUTICS, INC. (SRPT) reported Interest Expense of -$21.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. interest expense for the quarter ending 2026-06-30 was -$21.51M.
- SAREPTA THERAPEUTICS, INC. interest expense for the quarter ending 2026-03-31 was -$21.71M.
- SAREPTA THERAPEUTICS, INC. interest expense for the quarter ending 2025-12-31 was -$40.04M.
- SAREPTA THERAPEUTICS, INC. interest expense for the quarter ending 2025-09-30 was $1.90M, a 61.37% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. interest expense for fiscal 2025 was -$38.14M.
- SAREPTA THERAPEUTICS, INC. interest expense for fiscal 2024 was -$18.39M.
- SAREPTA THERAPEUTICS, INC. interest expense for fiscal 2023 was -$22.01M.
- SAREPTA THERAPEUTICS, INC. interest expense for fiscal 2022 was -$53.25M, a 183.82% decline from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$21.51M 10-Q · filed 2026-08-05 | -$43.22M 10-Q · filed 2026-08-05 | -$83.26M derived: sum of 3 quarters · filed 2026-08-05 | -$81.36M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$21.71M 10-Q · filed 2026-05-06 | -$61.75M derived: sum of 2 quarters · filed 2026-05-06 | -$59.85M derived: sum of 3 quarters · filed 2026-05-06 | -$65.08M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$40.04M derived: 10-K 12 month − 10-K 9 month · filed 2026-03-02 | -$38.14M derived: sum of 2 quarters · filed 2026-03-02 | -$43.37M derived: sum of 3 quarters · filed 2026-08-05 | -$38.14M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $1.90M 10-K · filed 2026-03-02 | $7.57M 10-Q · filed 2025-11-06 | -$3.33M derived: sum of 2 quarters · filed 2026-08-05 | $1.90M 10-K · filed 2026-03-02 | $17.30M 10-Q · filed 2025-11-06 | -$40.14M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | -$5.23M 10-Q · filed 2026-08-05 | $5.23M 10-Q · filed 2025-08-06 | -$9.73M 10-Q · filed 2026-08-05 | $9.73M 10-Q · filed 2025-08-06 | -$42.04M derived: sum of 3 quarters · filed 2026-08-05 | -$37.12M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$4.50M 10-Q · filed 2026-05-06 | -$36.81M derived: sum of 2 quarters · filed 2026-05-06 | -$31.89M derived: sum of 3 quarters · filed 2026-05-06 | -$27.06M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$32.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$27.39M derived: sum of 2 quarters · filed 2026-03-02 | -$22.56M derived: sum of 3 quarters · filed 2026-03-02 | -$18.39M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $4.92M 10-Q · filed 2025-11-06 | $9.75M derived: sum of 2 quarters · filed 2025-11-06 | $13.92M 10-Q · filed 2025-11-06 | -$33.20M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-06-30 | $4.83M 10-Q · filed 2025-08-06 | $9.00M 10-Q · filed 2025-08-06 | -$38.12M derived: sum of 3 quarters · filed 2026-03-02 | -$32.89M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-03-31 | -$4.17M 10-Q · filed 2025-05-06 | $4.17M 10-Q · filed 2024-05-01 | -$42.95M derived: sum of 2 quarters · filed 2026-03-02 | -$37.72M derived: sum of 3 quarters · filed 2026-03-02 | -$32.50M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | -$38.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$33.56M derived: sum of 2 quarters · filed 2026-03-02 | -$28.33M derived: sum of 3 quarters · filed 2026-03-02 | -$22.01M 10-K · filed 2026-03-02 | $22.01M 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $5.23M 10-Q · filed 2024-11-06 | $10.45M derived: sum of 2 quarters · filed 2024-11-06 | $16.78M 10-Q · filed 2024-11-06 | -$83.03M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $5.22M 10-Q · filed 2024-08-07 | $11.55M 10-Q · filed 2024-08-07 | -$88.26M derived: sum of 3 quarters · filed 2025-02-28 | -$73.53M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $6.32M 10-Q · filed 2024-05-01 | -$93.48M derived: sum of 2 quarters · filed 2025-02-28 | -$78.75M derived: sum of 3 quarters · filed 2025-02-28 | -$62.72M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | -$99.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$85.07M derived: sum of 2 quarters · filed 2025-02-28 | -$69.04M derived: sum of 3 quarters · filed 2025-02-28 | -$53.25M 10-K · filed 2025-02-28 | $53.25M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $14.74M 10-Q · filed 2023-11-01 | $30.76M derived: sum of 2 quarters · filed 2023-11-01 | $46.56M 10-Q · filed 2023-11-01 | $62.61M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $16.03M 10-Q · filed 2023-08-02 | $31.82M 10-Q · filed 2023-08-02 | $47.87M derived: sum of 3 quarters · filed 2024-02-28 | $63.87M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $15.80M 10-Q · filed 2023-05-02 | $31.84M derived: sum of 2 quarters · filed 2024-02-28 | $47.84M derived: sum of 3 quarters · filed 2024-02-28 | $63.67M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $16.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $32.04M derived: sum of 2 quarters · filed 2024-02-28 | $47.87M derived: sum of 3 quarters · filed 2024-02-28 | $63.52M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $15.99M 10-Q · filed 2022-11-02 | $31.83M derived: sum of 2 quarters · filed 2022-11-02 | $47.48M 10-Q · filed 2022-11-02 | $66.21M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $15.83M 10-Q · filed 2022-08-02 | $31.48M 10-Q · filed 2022-08-02 | $50.21M derived: sum of 3 quarters · filed 2023-02-28 | $64.10M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $15.65M 10-Q · filed 2022-05-04 | $34.38M derived: sum of 2 quarters · filed 2023-02-28 | $48.27M derived: sum of 3 quarters · filed 2023-02-28 | $61.98M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $32.62M derived: sum of 2 quarters · filed 2023-02-28 | $46.33M derived: sum of 3 quarters · filed 2023-02-28 | $59.95M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $13.89M 10-Q · filed 2021-11-03 | $27.60M derived: sum of 2 quarters · filed 2021-11-03 | $41.22M 10-Q · filed 2021-11-03 | $49.61M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $13.71M 10-Q · filed 2021-08-04 | $27.33M 10-Q · filed 2021-08-04 | $35.72M derived: sum of 3 quarters · filed 2022-03-01 | $43.24M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $13.62M 10-Q · filed 2021-05-05 | $22.00M derived: sum of 2 quarters · filed 2022-03-01 | $29.52M derived: sum of 3 quarters · filed 2022-03-01 | $36.95M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $15.91M derived: sum of 2 quarters · filed 2022-03-01 | $23.33M derived: sum of 3 quarters · filed 2022-03-01 | $30.67M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $7.52M 10-Q · filed 2020-11-05 | $14.94M derived: sum of 2 quarters · filed 2020-11-05 | $22.28M 10-Q · filed 2020-11-05 | $29.53M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $7.43M 10-Q · filed 2020-08-05 | $14.76M 10-Q · filed 2020-08-05 | $22.01M derived: sum of 3 quarters · filed 2021-03-01 | $32.69M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $7.33M 10-Q · filed 2020-05-06 | $14.58M derived: sum of 2 quarters · filed 2021-03-01 | $25.27M derived: sum of 3 quarters · filed 2021-03-01 | $33.41M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $17.93M derived: sum of 2 quarters · filed 2021-03-01 | $26.07M derived: sum of 3 quarters · filed 2021-03-01 | $33.71M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $10.68M 10-Q · filed 2019-11-07 | $18.83M derived: sum of 2 quarters · filed 2019-11-07 | $26.46M 10-Q · filed 2019-11-07 | $30.94M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $8.14M 10-Q · filed 2019-08-07 | $15.78M 10-Q · filed 2019-08-07 | $20.25M derived: sum of 3 quarters · filed 2020-02-26 | $21.06M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $7.63M 10-Q · filed 2019-05-08 | $12.11M derived: sum of 2 quarters · filed 2020-02-26 | $12.91M derived: sum of 3 quarters · filed 2020-02-26 | $13.18M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.28M derived: sum of 2 quarters · filed 2020-02-26 | $5.54M derived: sum of 3 quarters · filed 2020-02-26 | $5.80M 10-K · filed 2020-02-26 | $5.78M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $802.00K 10-Q · filed 2018-10-31 | $1.07M derived: sum of 2 quarters · filed 2018-10-31 | $1.32M 10-Q · filed 2018-10-31 | |||||
| 2017-06-30 | $265.00K 10-Q · filed 2018-08-08 | $523.00K 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | $257.00K 10-Q · filed 2018-05-03 | |||||||
| 2016-12-31 | $1.89M 10-K · filed 2019-02-28 | |||||||
| 2015-12-31 | $1.36M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |